Multi-kinase inhibitor

Regorafenib (Specialist drug)

Brand names: Stivarga

Regorafenib is an oral multikinase inhibitor used as a specialist treatment in metastatic colorectal cancer, gastrointestinal stromal tumour and hepatocellular carcinoma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits multiple kinases involved in tumour angiogenesis, oncogenesis and the tumour microenvironment, including VEGFR, KIT and RAF kinases.

Prescribing in practice

Severe and sometimes fatal hepatotoxicity can occur, so liver function must be checked before and frequently during the early weeks of treatment.
Hand-foot skin reaction and hypertension are common and may require dose modification.
Initiation is restricted to specialist oncology services familiar with multikinase inhibitor toxicity.

Monitoring

Monitor liver function tests, blood pressure and the skin (particularly palms and soles) regularly, especially early in treatment.

Counselling the patient

Report yellowing of the skin or eyes, dark urine or unusual tiredness promptly.
Tell the team about painful, blistering or peeling skin on the hands or feet.
Attend for regular blood pressure and blood test checks.

Evidence & guidelines

Use is supported by NICE guidance and pivotal trials including the CORRECT study in colorectal cancer.

Reference: NICE TA866/TA678; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways